Vertex Pharmaceuticals Incorporated
VRTX
$552.85
$5.260.96%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 21.10% | 538.70% | 838.09% | 865.96% | 842.52% |
| Total Depreciation and Amortization | 9.34% | 5.20% | -1.87% | -15.63% | -11.28% |
| Total Amortization of Deferred Charges | 23.81% | 23.81% | 23.81% | 113.56% | 113.56% |
| Total Other Non-Cash Items | -58.89% | -48.42% | 90.39% | 209.86% | 717.51% |
| Change in Net Operating Assets | 16.81% | 24.84% | -132.93% | -2.27% | -5.45% |
| Cash from Operations | 11.61% | 532.58% | 837.19% | 541.25% | 507.46% |
| Capital Expenditure | -43.29% | -96.41% | -46.99% | -44.68% | -46.84% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 71.69% | 44.26% | 85.38% | 69.24% | 59.52% |
| Cash from Investing | 48.38% | 21.78% | 74.92% | 61.42% | 52.55% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 58.21% | 86.27% | 91.67% | 93.91% | 86.65% |
| Issuance of Common Stock | 25.90% | 20.63% | 11.43% | -14.76% | -18.85% |
| Repurchase of Common Stock | -22.05% | -17.87% | -50.89% | -104.76% | -75.57% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 71.43% | -45.45% | -82.26% | -76.32% | -82.50% |
| Cash from Financing | -21.50% | -16.61% | -51.27% | -110.51% | -80.68% |
| Foreign Exchange rate Adjustments | -164.56% | 474.29% | 313.38% | 13.08% | 578.79% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 199.77% | 118.28% | 108.89% | 94.88% | 107.03% |